Millipore Sigma Vibrant Logo

PC322L Anti-VEGFR1 Goat pAb

View Products on Sigmaaldrich.com
PC322L
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      Species ReactivityHostAntibody Type
      HGtPolyclonal Antibody
      Description
      Overview

      This product has been discontinued.



      Recognizes VEGF receptor 1.

      Catalogue NumberPC322L
      Brand Family Calbiochem®
      SynonymsAnti-VEGF-R1, Anti-Flt-1, Anti-EMRK2, Anti-Vascular Endothelial Growth Factor Receptor
      References
      ReferencesSoker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Product Information
      FormLyophilized
      FormulationLyophilized from a sterile solution in PBS, 5% trehalose.
      Positive controlEndothelial cells
      PreservativeNone
      Quality LevelMQ100
      Applications
      Key Applications Competition Studies
      Enzyme-Linked Immunosorbent Assay
      Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesCompetition Studies (see comments)
      ELISA (0.5-1 µg/ml)
      Immunoblotting (0.1-0.2 µg/ml)
      Paraffin Sections (5-15 µg/ml)
      Application CommentsThis antibody has been selected for its ability to recognize human recombinant VEGFR-1 in immunoblotting and ELISA. The detection limit for human recombinant VEGFR-1 by immunoblotting is approximately 50 ng/lane under reducing and non-reducing conditions. The detection limit for human recombinant Flt-1 by ELISA is approximately 0.16 ng/well. At approximately 10 µg/ml this antibody will completely block the binding of rhPlGF (2 ng/ml) to immobilized rhVEGFR1/Fc (1 µg/ml; 100 µl/well). This antibody exhibits no cross-reactivity with other cytokines when tested in ELISA. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenrecombinant, human VEGFR1 (extracellular domain)/Fc chimera
      ImmunogenHuman
      HostGoat
      IsotypeIgG
      Species Reactivity
      • Human
      Antibody TypePolyclonal Antibody
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsReconstitute the lyophilized antibody in 1 ml sterile PBS. Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Avoid freeze/thaw cycles of solutions.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      PC322L 0

      Documentation

      Anti-VEGFR1 Goat pAb Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Anti-VEGFR1 Goat pAb Certificados de análisis

      CargoNúmero de lote
      PC322L

      Referencias bibliográficas

      Visión general referencias
      Soker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-July-2007 RFH
      SynonymsAnti-VEGF-R1, Anti-Flt-1, Anti-EMRK2, Anti-Vascular Endothelial Growth Factor Receptor
      ApplicationCompetition Studies (see comments)
      ELISA (0.5-1 µg/ml)
      Immunoblotting (0.1-0.2 µg/ml)
      Paraffin Sections (5-15 µg/ml)
      DescriptionImmunoaffinity purified goat polyclonal antibody. Recognizes the VEGF receptor 1 protein.
      BackgroundVascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a secreted heparin binding cytokine expressed in tumor and animal cells. VEGF has been implicated in the control of angiogenesis due to its selective mitogenic stimulation of vascular endothelial cells and enhancement of vascular permeability. VEGF is a ~34-50 kDa dimer of two identical disulfide-linked subunits existing in four molecular species; 121, 165, 189, and 206 amino acid residues long, arising from alternative splicing of a single gene. VEGF binds to two receptor tyrosine kinases, Flt-1 (VEGFR1) and KDR/Flk-1 (VEGFR2) found almost exclusively on human endothelial cells. Flt-1 binds VEGF and a new VEGF-related ligand, placenta growth factor (PIGF) but KDR/Flk-1 binds only VEGF. The cDNA encoding the soluble truncated form of Flt-1 cloned from a human endothelial cell library encodes the 6 N-terminal IgG-like extracellular ligand-binding domain but does not encode the transmembrane spanning region and intracellular tyrosine kinase domains. The recombinant soluble receptor binds avidly to VEGF and is a potent VEGF antagonist. Recently, a third VEGF receptor was identified and cloned from tumor cells. This VEGF receptor is isoform-specific, binding VEGF165 but not VEGF121. Studies indicate that this VEGF receptor (VEGF165R) is identical to human neuropilin-1, a receptor for the collapsin/semaphorin family that mediates neuronal cell guidance.
      HostGoat
      Immunogen speciesHuman
      Immunogenrecombinant, human VEGFR1 (extracellular domain)/Fc chimera
      IsotypeIgG
      Specieshuman
      Positive controlEndothelial cells
      FormLyophilized
      FormulationLyophilized from a sterile solution in PBS, 5% trehalose.
      PreservativeNone
      CommentsThis antibody has been selected for its ability to recognize human recombinant VEGFR-1 in immunoblotting and ELISA. The detection limit for human recombinant VEGFR-1 by immunoblotting is approximately 50 ng/lane under reducing and non-reducing conditions. The detection limit for human recombinant Flt-1 by ELISA is approximately 0.16 ng/well. At approximately 10 µg/ml this antibody will completely block the binding of rhPlGF (2 ng/ml) to immobilized rhVEGFR1/Fc (1 µg/ml; 100 µl/well). This antibody exhibits no cross-reactivity with other cytokines when tested in ELISA. Antibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsReconstitute the lyophilized antibody in 1 ml sterile PBS. Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Avoid freeze/thaw cycles of solutions.
      Toxicity Standard Handling
      ReferencesSoker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.